Adler C H, Meller E, Goldstein M
Eur J Pharmacol. 1985 Oct 8;116(1-2):175-8. doi: 10.1016/0014-2999(85)90200-6.
Treatment of rats with N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) resulted in a pronounced loss of alpha 2-adrenoceptor binding ( [3H]RX-781094) and a marked reduction in the ability of the alpha 2-agonist UK-14,304 to inhibit K+-stimulated release of both [3H]NA and [3H]5-HT in cerebral cortex. Repopulation of alpha 2-adrenoceptors was monoexponential with a t1/2 of 4.1 days; functional recovery was also monoexponential, with t1/2 values of 2.4 and 4.6 days for restoration of alpha 2-mediated inhibition of [3H]NA and [3H]5-HT release, respectively. Other studies suggest the difference in functional recovery rate may reflect the presence of a large receptor reserve for autoreceptors relative to heteroreceptors.
用N - 乙氧羰基 - 2 - 乙氧基 - 1,2 - 二氢喹啉(EEDQ)处理大鼠,导致α2 - 肾上腺素能受体结合([3H]RX - 781094)显著丧失,并且α2 - 激动剂UK - 14,304抑制大脑皮层中K + 刺激的[3H]去甲肾上腺素(NA)和[3H]5 - 羟色胺(5 - HT)释放的能力明显降低。α2 - 肾上腺素能受体的重新填充呈单指数形式,半衰期为4.1天;功能恢复也呈单指数形式,α2介导的对[3H]NA和[3H]5 - HT释放抑制的恢复的半衰期分别为2.4天和4.6天。其他研究表明,功能恢复率的差异可能反映了相对于异受体而言,自身受体存在大量的受体储备。